New research suggests that weight gained in the first 12 weeks of antipsychotic treatment is the biggest driver of long-term obesity in psychosis.
[read the full story...]Can we predict and prevent weight gain in early psychosis?
No Responses »
Stop, reduce or stay on antipsychotics after first-episode psychosis?
Once symptoms stabilise after a first episode of psychosis, should medication continue? A four-year RCT explores the risks and rewards of dose reduction.
[read the full story...]Metformin reduces weight gain in young people taking antipsychotics
Large pragmatic trial found metformin plus lifestyle intervention reduced weight gain in young people with bipolar disorder taking antipsychotics. Effect significant but modest at 6 and 24 months.
[read the full story...]Do antipsychotics slow down thinking? New evidence from healthy volunteers
New research reveals how antipsychotic medications affect working memory speed in healthy adults, providing crucial insights into the cognitive side effects of these widely prescribed drugs.
[read the full story...]Rapid weight gain after SMI diagnosis, but why so few referrals for support?
A 15-year analysis of UK primary care records showed steep and sustained weight gain after an SMI diagnosis, especially among younger adults and people prescribed antipsychotic medication. Yet very few received referrals for weight-management support, raising important questions about practice and policy.
[read the full story...]Should you start metformin whenever you start antipsychotics?
Guidelines say metformin can help prevent weight gain from antipsychotics like olanzapine, but this large UK study shows it’s rarely prescribed. What’s stopping us?
[read the full story...]Treating ADHD in psychosis: What does the evidence say about safety?
How safe is it to treat ADHD in people with schizophrenia spectrum disorders? New long-term data offers pragmatic reassurance, but also some warnings.
[read the full story...]Clozapine and infection risk: new evidence from Hong Kong’s 20-year cohort study
Clozapine is described as the gold standard treatment for schizophrenia but a new cohort study suggests it is associated with an increased risk of infections, particularly in older patients, further solidifying the case for holistic care.
[read the full story...]Prescribing in borderline personality disorder: Evidence, relationships, and the realities of practice
No drugs are officially approved for borderline personality disorder, yet prescribing is widespread. This systematic review explores why clinicians prescribe, the pressures they face, and what it means for patient care.
[read the full story...]Do psychiatric disorder genes overlap with their drug targets? And does this matter?
Psychiatric disorders are highly heritable, but are the genes we identify in GWAS the same ones our medications target? This new study digs into the overlap and raises questions about how we develop treatments.
[read the full story...]